Home > Members > Board Resources > Electronic Mailbag > August 2026 Electronic Mailbags

---

Committee and Task Force Appointments

Attached are the committee, task force, and work group appointments made by NABP President Nicki Chopski, PharmD, ANP.

NABP received an overwhelming response from members interested in volunteering for a committee or task force. President Chopski worked earnestly to involve as many people as possible, with a focus on appointing individuals who may be new to their state boards of pharmacy, new to NABP, or have not previously served on a committee or task force. The intent in this approach is to broaden participation in NABP and foster the involvement of new members in the Association.

Attachment

back to top

DSCSA Exemptions from Certain Requirements Under Section 582 of the FD&C Act for Small Business Dispensers Until November 27, 2027

FDA DSCSA Exemptions for Small Dispensers

On August 6, 2026, the FDA announced it is granting exemptions from certain Drug Supply Chain Security Act (DSCSA) requirements under section 582 of the FD&C Act to small dispensers (e.g., pharmacies) and their applicable trading partners.

Key Dates:

• September 22, 2026 — Deadline for small dispensers to complete the small dispensers assessment survey
• November 27, 2026 — Cutoff date for determining eligibility as a “small dispenser” (companies with 25 or fewer full-time pharmacists/pharmacy technicians as of this date)
• November 27, 2027 — Exemption expiration date; small dispensers must comply with enhanced drug distribution security requirements by this deadline

Survey Request:

FDA is specifically encouraging small dispensers to complete the small dispensers assessment survey by September 22, 2026. Small dispensers may designate a third party (e.g., a consultant) to complete the survey on their behalf. The exemption period exists specifically to allow time to complete this assessment, publish the final report for public comment, and hold a public meeting on the results.

Other Notes:

• Small dispensers and trading partners using these exemptions do not need to notify or submit anything to FDA.
• Trading partners that don’t qualify for the exemption may request a waiver or exemption through CDER NextGen (CDER-regulated products) or via email for CBER-regulated products.

back to top

Engagement of Compounding Strategy Advisors to Support Compounding Oversight

The National Association of Boards of Pharmacy (NABP) is pleased to announce that it has engaged Compounding Strategy Advisors (CSA) to help shape and execute NABP’s compounding oversight strategy.

As compounding volumes continue to grow, so do the related oversight questions. In this environment, it is necessary for NABP to act quickly and provide boards with practical, well-grounded tools. CSA will provide support for this and brings deep 503A and 503B regulatory and compounding expertise through its advisors, Kathy Anderson, Ilisa Bernstein, and Gail Bormel.

CSA will assist NABP in three areas: oversight and inspection programs for outsourcing facilities, education and safety related to peptide compounding, and adverse event reporting and data sharing among states and with federal partners. As part of the peptide work, CSA will help NABP explore with the states the need for peptide compounding inspections.

CSA serves as a contracted expert advisor. NABP continues to set the strategy and direction of this work, and NABP’s focus remains what it has always been: protecting patient safety.

NABP will provide additional detail and answer questions during the 50-state executive officer call on August 21, 2026.

back to top

Webinar on Peptide Regulation: Board Compliance Officers Are Invited to Attend

NABP is pleased to expand the webinar audience to include compliance officers and investigators of the boards of pharmacy and colleges of pharmacists.

NABP is hosting a complimentary educational webinar for compliance officers, investigators, attorneys, and executive officers and registrars of the United States boards of pharmacy and Canada colleges of pharmacists, respectively: GLP-1 Medications, Peptides & the Evolving Regulatory Landscape. Webinar topics include the regulatory status of the peptide compounding by state-licensed pharmacies and outsourcing facilities. The webinar will take place on Thursday, October 8, 2026, at 1:00 PM Central Daylight Time.

In early September, NABP will send registration information for the webinar to the executive officers and registrars. We ask you to forward the registration information to the approved staff and attorneys who will attend the webinar.

If you have any questions, do not hesitate to email the Legal Affairs team at legalaffairs@nabp.pharmacy.

We sincerely look forward to you and your team joining us for the October webinar!

back to top

FDA Letter on Compounded GLP-1 Multidose Vial Labeling

NABP is forwarding the attached letter from the United States Food and Drug Administration (FDA) regarding the labeling of compounded glucagon-like peptide-1 (GLP-1) receptor agonist medications and the handling of multidose vials.

FDA has identified an increase in patient complaints related to compounded GLP-1 multidose vials. Concerns include patients being dispensed vial volumes that far exceed what would be administered within the standard 28-day beyond-use period after first puncture, as well as patients being advised to use vials beyond that 28-day limit.

FDA notes that compounded GLP-1 products often differ from FDA-approved products in concentration, and prescription labeling and dosing instructions may be confusing or difficult for patients to accurately follow. Depending on where a patient is in their dosing regimen, a significant portion of vial contents may need to be discarded. Additionally, some compounded GLP-1 products contain additional active ingredients such as vitamins or supplements, which may further increase the risk of dosing errors.

FDA recommends that clear discard instructions be provided to patients. For example, for a patient on once-weekly dosing: “Discard vial after the 4^th injection.”

NABP encourages executive officers to share this information with members of their boards of pharmacy and to remain attentive to compounding activities related to GLP-1 medications in their jurisdictions.

If you have any questions or wish to submit relevant information to FDA, contact the Office of Compounding Quality and Compliance via email at compounding@fda.hhs.gov.

Attachment: FDA Letter, Compounded GLP-1 Multi-Dose Vial Labeling and Handling, August 12, 2026

back to top

FPGEC Communication Skills Requirement Update

NABP is notifying the boards of pharmacy of updates to the communication skills requirement for the Foreign Pharmacy Graduate Examination Committee (FPGEC) program. These changes were identified by the 2025 Task Force to Examine the Use of the TOEFL iBT as a Requirement for FPGEC Certification.

Candidates wishing to be evaluated and accepted to sit for Foreign Pharmacy Graduate Equivalency Examination administrations in 2027 and beyond will now have more options to fulfill the communication skills requirement:

• Beginning in November 2026, candidates who take the Test of English as a Foreign Language Internet-based Test (TOEFL iBT) may use MyBest scores.
• Beginning on January 11, 2027, FPGEC candidates may use the Occupational English Test (OET) as an accepted assessment for communication skills.

The FPGEC Candidate Application Bulletin and NABP website will be updated with details about both changes in October 2026. The standard setting for OET will take place in late October this year, and once the scores are approved, the information will be added to the Bulletin.

If you have any questions, contact Jasmina Bjegovic, Chief Officer, Exam Services, via email at jbjegovic@nabp.pharmacy.

back to top